Neutrophil-derived reactive oxygen species mediate doxorubicin-induced cardiotoxicity and skeletal myopathy

American Journal of Physiology-Heart and Circulatory Physiology 2026

View at publisher
Authors: Kasia Dzierlega, Amro Mohamed Soliman, Huachen Chen, Jennie Vu, D J Parker, Blake Roberts, Mitchell J. Wagner, Aklima Akter, Maya Hassane, Tolga Kilic, Jonas Wong, Masoud Akbari
+4 more Wael Elhenawy, Gavin Y. Oudit, Sue Jean Tsai, Xavier Clemente‐Casares
DOI: 10.1152/ajpheart.00720.2025
Cited by: 0
References: 43

Abstract

DOX is a commonly used cancer treatment, but its severe side effects, limit its clinical use. This research highlights neutrophil-derived reactive oxygen species (ROS) production through the NOX2 complex as a key contributor to this myopathy, offering a potential therapeutic to protect against cardiotoxicity without compromising DOX's anticancer benefits. These insights open new avenues for safer, more effective cancer treatments.

Fields of Study & Subjects

Chemotherapy-induced cardiotoxicity and mitigation Bioactive Compounds and Antitumor Agents Chemotherapy-related skin toxicity

Publication details

Journal / source
American Journal of Physiology-Heart and Circulatory Physiology
Volume
330
Issue
4
Pages
H1092–H1101
Publication date
12 February 2026
Language
EN